A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Prior treatment

• Previous or co-existing malignancies.
• Spinal cord compression that was not treated radically by surgery and/or radiotherapy was excluded.
• Have undergone major surgery other than diagnosis or biopsy within 28 days prior to the initial dosing; Minor traumatic surgery within 7 days prior to the first dosing.
• Received other investigational drugs treatments 4 weeks prior to the initiation of the study treatment.
• Unresolved CTCAE 5.0\>grade 2 toxicities from previous anticancer therapy.
• Severe infection 30 days before the first dose.

Other illness

• With poorly controlled or severe cardiovascular disease.
• Active hepatitis B and hepatitis C.
• Patients with a history of immunodeficiency.

Other

• Meningeal metastasis history or clinical symptoms of central nervous system metastasis.
• Uncontrollable tumor-related pain.

• Voluntary participation and written informed consent.
• 18-75 years older, no gender limitation.
• Eastern Cooperative Oncology Group (ECOG) score: 0-1.
• With a life expectancy ≥ 3 months.
• Pathologically diagnosed NSCLC.
• Be able to provide fresh or archived tumour tissue.
• At least one measurable lesion according to RECIST v1.1.
• Adequate organ function.
• Contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose.